Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease

Inclusion Criteria:

* Histologically documented unresectable stage III NSCLC. Mediastinal (N2) involvement must be confirmed by biopsy
* Stable disease or clinical response after primary therapy of chemo-radiation treatment for unresectable stage III disease
* Primary therapy should be a minimum of 2 cycles of Platinum-based first-line chemotherapy, given concurrent with thoracic radiation. The combined modality should consist of either:

  * induction (2 cycles) chemotherapy followed by concurrent chemo-radiation therapy; or
  * concurrent chemo-radiation therapy followed by 2 cycles of consolidation chemotherapy; or
  * concurrent chemoradiation therapy alone
* A minimum radiation dose of greater than or equal to (\>=) 6,000 centigray (cGy) should be administered. Subjects must have completed the primary therapy at least 4 weeks and no later than 6 months prior to study entry
* Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to (\<=) 1
* Ability to understand and willingness to sign a written informed consent
* Other protocol defined inclusion criteria could apply

Exclusion Criteria:

* Undergone lung cancer specific therapy (including surgery) prior to primary chemo-radiation therapy
* Received immunotherapy/systemic immunosuppressive drugs/investigational systemic drugs within 4 weeks prior to study entry
* Subjects with brain metastases, pleural effusion, unless cytologically confirmed to be non-malignant
* Past or current history of neoplasm other than lung carcinoma, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years
* Autoimmune disease or immunodeficiency
* Clinically significant hepatic, renal dysfunction or cardiac diseases
* Clinically significant active infection
* Pregnant or lactating, women of childbearing potential, unless using effective contraception as determined by the investigator
* Other protocol defined inclusion criteria could apply